Mesoblast has an intellectual property portfolio of more than 1000 patents or patent applications including the use of mesenchymal stem cells/mesenchymal stromal cells (MSCs) for treatment of patients with acute respiratory distress syndrome (ARDS), inflammatory lung disease due to COVID-19, influenza and other viruses.
Their MSC product called Remestemcel-L is being testing in clinical trials for inflammatory conditions including elderly patients with lung disease and adults and children with steroid-refractory acute graft-vs.-host disease (aGVHD). Mesoblast’s stem cell therapy is under review by the FDA for treatment of children with steroid-refractory aGVHD. Remestemcel-L is being developed for rare pediatric and adult inflammatory conditions. The product is comprised of culture-expanded MSCs derived from bone marrow of an unrelated donor (allogeneic) that is administered in a series of intravenous infusions. The therapy is thought to have immunomodulatory properties which counteract inflammatory processes including down-regulation of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines and enabling recruitment of anti-inflammatory cells already in the body to the diseased tissue. Remestemcel-L is previously known under the product name Prochymal by the company Osiris Therapeutics. In 2013 Mesoblast acquired Prochymal and Osiris’ culture-expanded mesenchymal stem cell business.
As of March 2020, Mesoblast has plans to evaluate its allogeneic mesenchymal stem cell (MSC) candidate, remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 in the US, Australia, China and Europe. ARDS is the and immune system overreaction to the virus in the lungs that causes severe damage to lung tissue. Allogeneic MSCs have been reported to cure or significantly improve functional outcomes of seven treated patients with severe COVID-19 pneumonia in a clinical study in China. Remestercel-L infusions have been tested on patients with chronic obstructive pulmonary disease (COPD) shown to be well tolerated, reduce inflammatory biomarkers and improve pulmonary function in patients with elevated inflammatory biomarkers. The same inflammatory markers are elevated in patients with ARDS due to COVID-19.
Ljiljana Minwalla, J.D., Ph.D.
Phase 3 Trial of Mesoblast's Cell Therapy in Chronic Heart Failure Completes Recruitment
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.